Anthony K. Ogawa
Anthony K. Ogawa has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Alejandro Crespo
Merck & Co., Inc., Rahway, NJ 07065, United States
2 shared publicationsBeata Zamlynny
Merck & Co., Inc., Rahway, NJ 07065, United States
2 shared publicationsKun Liu
Merck & Co., Inc., Rahway, NJ 07065, United States
2 shared publicationsThomas Bateman
Merck & Co., Inc., Rahway, NJ 07065, United States
2 shared publicationsAlan Hruza
Discovery Chemistry
1 shared publicationAlexandra Wickham
In Vivo Pharmacology
1 shared publication
Latest Publications
- 14 August 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (9) , 3090-3100
The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors
Despite advances in anticoagulant drug discovery to establish a new standard of care, represented by Factor Xa (FXa) inhibitors, additional therapies are needed to address the concomitant bleeding risk posed by these agents. Factor XI (FXI) plays a key role in the intrinsic coagulation cascade contributing to thrombin generation and fibril formation, and there is an increasing weight of evidence supporting a comparable efficacy and superior safety profile of FXI-based oral anticoagulants. A novel allosteric mechanism of action (MoA) for inhibiting FXI activation to Factor XIa (FXIa) was discovered by applying an AS-MS-based screen to the FXI zymogen. Biochemical and biophysical characterization of these structurally diverse small-molecule classes confirmed this mode of inhibition as specific to the FXI zymogen, and a high-resolution FXI-inhibitor cocomplex structure identified the binding pocket that is distal to the FXI cleavage site. These FXI Activation Inhibitors were active in translational functional assays, prolonging activated partial thromboplastin time (aPTT) in human plasma and demonstrating dose-dependent antithrombotic effects in the rabbit arteriovenous-shunt model of thrombosis. The results affirm that FXI Activation Inhibitors are a novel mechanism for the potential treatment of thrombotic disorders.
- 14 August 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (9) , 3090-3100
The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors
Despite advances in anticoagulant drug discovery to establish a new standard of care, represented by Factor Xa (FXa) inhibitors, additional therapies are needed to address the concomitant bleeding risk posed by these agents. Factor XI (FXI) plays a key role in the intrinsic coagulation cascade contributing to thrombin generation and fibril formation, and there is an increasing weight of evidence supporting a comparable efficacy and superior safety profile of FXI-based oral anticoagulants. A novel allosteric mechanism of action (MoA) for inhibiting FXI activation to Factor XIa (FXIa) was discovered by applying an AS-MS-based screen to the FXI zymogen. Biochemical and biophysical characterization of these structurally diverse small-molecule classes confirmed this mode of inhibition as specific to the FXI zymogen, and a high-resolution FXI-inhibitor cocomplex structure identified the binding pocket that is distal to the FXI cleavage site. These FXI Activation Inhibitors were active in translational functional assays, prolonging activated partial thromboplastin time (aPTT) in human plasma and demonstrating dose-dependent antithrombotic effects in the rabbit arteriovenous-shunt model of thrombosis. The results affirm that FXI Activation Inhibitors are a novel mechanism for the potential treatment of thrombotic disorders.
- 1 July 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (14) , 1854-1858
Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization
- 1 July 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (14) , 1854-1858
Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization
- 1 June 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (12) , 2866-2869
Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists
- 1 June 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (12) , 2866-2869
Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists
- 21 October 2000
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 122 (44) , 10743-10753
Chemically Reactive Immunogens Lead to Functional Convergence of the Immune Response
- 21 October 2000
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 122 (44) , 10743-10753
Chemically Reactive Immunogens Lead to Functional Convergence of the Immune Response
- 20 November 1998
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 120 (48) , 12435-12442
Total Synthesis of Calyculin C
- 20 November 1998
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 120 (48) , 12435-12442
Total Synthesis of Calyculin C